Results 201 to 210 of about 28,830 (241)
Some of the next articles are maybe not open access.
Journal of the Association of Nurses in AIDS Care, 2000
Item does not contain ...
Aarnoutse, R.E. +2 more
+6 more sources
Item does not contain ...
Aarnoutse, R.E. +2 more
+6 more sources
Drugs, 1998
Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) which shows good inhibitory activity against HIV-1. Reduced susceptibility to efavirenz has been reported with HIV-1 variants containing single and multiple mutations to the reverse transcriptase enzyme.
J C, Adkins, S, Noble
openaire +2 more sources
Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) which shows good inhibitory activity against HIV-1. Reduced susceptibility to efavirenz has been reported with HIV-1 variants containing single and multiple mutations to the reverse transcriptase enzyme.
J C, Adkins, S, Noble
openaire +2 more sources
Expert Opinion on Pharmacotherapy, 2007
Treatment of HIV infection is typically carried out using a combination of at least three drugs. Efavirenz is a non-nucleoside reverse transcriptase inhibitor that acts by non-competitive inhibition of the viral enzyme. Efavirenz-based regimens have performed favorably compared with protease inhibitor-based therapies either in naive patients or as ...
openaire +3 more sources
Treatment of HIV infection is typically carried out using a combination of at least three drugs. Efavirenz is a non-nucleoside reverse transcriptase inhibitor that acts by non-competitive inhibition of the viral enzyme. Efavirenz-based regimens have performed favorably compared with protease inhibitor-based therapies either in naive patients or as ...
openaire +3 more sources
CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz
Clinical Infectious Diseases, 2021Rulan Griesel +2 more
exaly